乙型肝炎患者血清miR-27a miR-625表达及与肝硬化和肝癌的相关性研究

doi:10.3969/j.issn.1006-6233.2021.12.004

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1303 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the expression levels of microRNA-27a (miR-27a) and microRNA-625 (miR-625) in serum of patients with hepatitis B and their correlations with liver cirrhosis and liver cancer. Methods: From November 2019 to February 2021, 67 patients with chronic hepatitis B were selected as hepatitis B group, 63 patients with post hepatitis B cirrhosis as cirrhosis group, 65 patients with post hepatitis B liver cancer as liver cancer group in department of gastroenterology, the Third Affiliated Hospital of Chengdu Medical College, and 65 healthy people as control group. The levels of serum miR-27a and miR-625 were detected by real-time fluorescent quantitative PCR; and multivariate Logistic regression analysis was used to analyze the factors influencing the occurrences of cirrhosis and liver cancer after hepatitis B; and receiver operating characteristic curve was used to evaluate the value of serum miR-27a, miR-625 levels predicting the occurrences of cirrhosis and liver cancer after hepatitis B. Results: The levels of miR-27a in control group, hepatitis B group, liver cirrhosis group and liver cancer group were increased in turn, while the levels of miR-625 were decreased in turn (P<0.05). Serum miR-27a level was an independent risk factor for the occurrence of liver cirrhosis and liver cancer after hepatitis B (P<0.05), serum miR-625 level was a protective factor for the occurrence of liver cirrhosis and liver cancer after hepatitis B (P<0.05). The area under the curve (AUC) of serum miR-27a, miR-625 and their combination in predicting the occurrence of liver cirrhosis after hepatitis B were 0.708 (95% CI: 0.620~0.797), 0.761 (95% CI: 0.680~0.843) and 0.815 (95% CI: 0.743~0.888), respectively. The sensitivity was 73.02%, 68.25% and 65.08%, and the specificity was 61.19%, 73.13% and 85.07%, respectively. The AUC of serum miR-27a, miR-625 and their combination in predicting HCC after hepatitis B were 0.870 (95% CI: 0.812~0.929), 0.913 (95% CI: 0.864~0.963) and 0.966 (95% CI: 0.938~0.993), respectively, with sensitivity of 79.23%, 76.92% and 73.64%, specificity of 66.57%, 72.54% and 89.55%, respectively. Conclusion: The expression of miR-27a in serum of patients with hepatitis B is up-regulated, the expression of miR-625 is down-regulated, and they are the independent risk factor and protective factor that affect the progression of hepatitis B to cirrhosis and liver cancer, which have certain predictive value for the occurrence of liver cirrhosis and liver cancer after hepatitis B.

Key words： Hepatitis B MicroRNA-27a MicroRNA-625 Liver cirrhosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.12.004 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I12/1957

[1] Colson P,Boschi C,BengoneAbogourin JG,et al.Concurrent nanopore next-generation sequencing of hepatitis B and delta virus genomes directly from patient plasma[J].Ann Lab Med,2021,41(6):608~611.
[2] 杨美荣,孟冬梅,方正亚.乙型肝炎后肝硬化并发原发性肝癌患者乙型肝炎病毒定量检测的临床意义[J].中国现代医学杂志,2019,29(1):76~79.
[3] Song J,Hu Y,Zheng H,et al.Comparative analysis of putative novel microRNA expression profiles induced by enterovirus 71 and coxsackievirus A16 infections in human umbilical vein endothelial cells using high-throughput sequencing[J].Infect Genet Evol,2019,73(1):401~410.
[4] Zhang H,Yan XL,Guo XX,et al.MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis[J].Oncotarget,2018,9(1):1075~1090.
[5] Ghaempoor M,Arefian E,Mohebbi SR,et al.Circulating miR-625 as an emerging biomarker for liver cirrhosis[J].Clin lab,2019,65(4):704~711.
[6] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].中华肝脏病杂志,2019,27(12):938~961.
[7] 中华医学会肝病学分会.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408~2425.
[8] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中华消化外科杂志,2020,19(1):1~20.
[9] 刘芷希,汪业胜,王伟炳.中国1990-2017年乙型肝炎疫情的变化趋势研究[J].中华流行病学杂志,2021,42(4):613~619.
[10] 林升龙,王香梅,马华晳,等.基于芯片和公共数据库数据分析微RNA在乙型肝炎病毒感染中的可能机制[J].中华传染病杂志,2020,38(11):717~722.
[11] 徐兰锋,王倩,刘洪玲,等.血清MicroRNA 122和MicroRNA-130a水平在隐匿性乙型肝炎病毒感染中的诊断价值初探[J].河北医学,2020,26(3):366~370.
[12] Tan X,Jiang L,Wu X,et al.MicroRNA-625 inhibits the progression of non-small cell lung cancer by directly targeting HOXB5 and deactivating the Wnt/β-catenin pathway[J].Int Mol Med,2019,44(1):346~356.
[13] 傅德强,许天文,吴文艺,等.微小RNA-27a在肝癌组织的表达及其机制[J].中华实验外科杂志,2016,33(4):1091~1093.